Telavancin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections

August 30, 2015 at 3:26 pm

Clinical Infectious Diseases SEP 15, 2015 V.61 Suppl.2 S35-S37

Keith A. Rodvold

Colleges of Pharmacy and Medicine, University of Illinois at Chicago

Correspondence: Keith A. Rodvold, PharmD, FCCP, FIDSA, University of Illinois at Chicago, College of Pharmacy, M/C 886, 833 S Wood St, Rm 164, Chicago, IL 60612 (

Methicillin-resistant Staphylococcus aureus (MRSA) causes a wide range of infections, including skin and skin-structure infections, pneumonia, bloodstream infections, and endocarditis [1].

Staphylococci, including MRSA, are considered to be a leading cause of healthcare-associated infections [2]. Many of these infections can be life-threatening and cause sepsis and death.

The Centers for Disease Control and Prevention estimate that 80 461 severe MRSA infections and 11 285 MRSA-related deaths occur each year in the United States [2].

The changing epidemiology and increasing prevalence of resistant phenotypes of S. aureus, including MRSA, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and, rarely, vancomycin-resistant S. aureus, have spurred the need for new antimicrobial agents to treat serious infections caused by these gram-positive pathogens.


Telavancin is a semisynthetic lipoglycopeptide antibacterial with potent bactericidal activity against a broad spectrum of these gram-positive organisms, including MRSA [3].

The recommended dosage regimen for telavancin is 10 mg/kg body weight intravenously infused over a 60-minute period every 24 hours in patients with normal renal function (creatinine clearance [CrCl], >50 mL/min).

A dosage adjustment is required for patients with renal impairment (CrCl, ≤50 mL/min). This supplement provides historical and current perspectives on the present roles of telavancin in clinical practice.




Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Health Care-Associated Infections, Infecciones asociadas a catater IV, Infecciones cardio-vasculares, Infecciones en piel y tej blandos, Infecciones nosocomiales, Infecciones respiratorias, Metodos diagnosticos, Resistencia bacteriana, Sepsis, Update.

Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response Evolving Resistance Among Gram-positive Pathogens


August 2015
« Jul   Sep »

Most Recent Posts

%d bloggers like this: